

1146
RECEIVED

JAN 28 2003

TECH CENTER 1600/2900

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
10793/50

Application Number
10/029,926

Filing Date
December 31, 2001

Examiner
To Be assigned


Art Unit
1646

Invention Title
SPECIFIC HUMAN ANTIBODIES FOR
SELECTIVE CANCER THERAPY

Inventor(s)
HAGAY et al.


Address to:
Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date: 1/23/03
Signature: 
Kathryn M. Lumb, Reg. No. 46,885

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: 1/23/03

By: 
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 28 2003
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
10793/50

Application Number
10/029,926

Filing Date
December 31, 2001

Examiner
To Be assigned

Art Unit
1646

Invention Title
SPECIFIC HUMAN ANTIBODIES FOR
SELECTIVE CANCER THERAPY

Inventor(s)
HAGAY et al.

Address to:
Commissioner for Patents
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date:

1/23/03

Signature:

Kathryn M. Lumb
Kathryn M. Lumb, Reg. No. 46,885


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: 1/23/03

By:

Kathryn M. Lumb
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)



RECEIVED
JAN 28 2003
TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT BY
APPLICANT PTO-1449**

ATTY. DOCKET NO.
10793/50

SERIAL NO.
10/029,900

APPLICANT
HAGAY et al.

FILING DATE
December 31, 2001

GROUP
1646

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	5,168,062	December 1, 1992	Stinski			
	5,385,839	January 31, 1995	Stinski			
	6,132,730	October 17, 2000	Thorpe, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Adams, G.P. et al., "Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu," British Journal of Cancer (1998) Vol. 77, No. 9, pp. 1405-1412
		Afshar-Kharghan, Vahid et al., "Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region," Blood, Vol. 97, No. 10, May 15, 2001, pp. 3306-3307
		Altman, John D. et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," Science, Vol. 274, October 4, 1996, pp. 94-96
		Bundgaard, Jens R. et al., "New Consensus Features for Tyrosine O-Sulfation Determined by Mutational Analysis," The Journal of Biological Chemistry, Vol. 272, No. 35, August 29, 1997, pp. 21700-21705
		Clezardin, Philippe et al., "Role of Platelet Membrane Glycoproteins Ib/Ix and Iib/IIIa, and of Platelet α-Granule Proteins in Platelet Aggregation Induced by Human Osteosarcoma Cells," Cancer Research, Vol. 53, October 1, 1993, pp. 4695-4700
		Cochran, Jennifer R. et al., "The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II Oligomers," Immunity, Vol. 12, March 2000, pp. 241-250
		de Kruijff, John et al., "Leucine Zipper Dimerized Bivalent and Bispecific scFv Antibodies from a Semi-synthetic Antibody Phage Display Library," The Journal of Biological Chemistry, Vol. 271, No. 13, March 29, 1996, pp. 7630-7634
		Gasic, Gabriel J. et al., "Antimetastatic Effects Associated with Platelet Reduction," Proc. Natl. Acad. Sci. USA, Vol. 61, 1968, pp. 46-52
		Gilbert, Walter et al., "The LAC Operator is DNA," Proc. Natl. Acad. Sci. USA, Vol. 58, 1967, p. 2415-2421
		Harrison, Jacqueline L. et al., "Screening of Phage Antibody Libraries," Methods in Enzymology, Vol. 267, 1996, pp. 83-109
		Roberts, Jeffrey W. et al., "Lysogenic Induction," Lambda II, Cold Spring Harbor Laboratory, 1983, pp. 123-144



EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Hudson, Peter J. et al., "Recombinant antibody constructs in cancer therapy," Current Opinion in Immunology, Vol. 11, 1999, pp. 548-557
	Jurcic, J.G. et al., "Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33)," Blood, 90(suppl.): 504a, 1997
	Kamiyama, Mikio et al., "Inhibition of Human Platelet Glycoprotein IIB/IIIA Binding to Fibrinogen by Tumor Cell Membrane Ptoeins," Cancer Research, Vol. 53, January 15, 1993, pp. 221-223
	Karpatkin, S. et al., "Role of Adhesive Proteins in Platelet Tumor Interaction in Vitro and Metastasis Formation In Vivo," J. Clin. Invest., Vol. 81, April 1988, pp. 1012-1019
	Kehoe, John W. et al., "Tyrosine sulfation: a modulator of extracellular protein-protein interactions," Chemistry & Biology, Vol. 7, No. 3, 2000, pp. R57-R61
	Kieffer, Nelly et al., "Expression of Platelet Glycoprotein Iba in HEL Cells," The Journal of Biological Chemistry, Vol. 261, No. 34, December 5, 1986, pp. 15854- 15862
	Kipriyanov, Sergey M. et al., "Single-chain antibody streptavidin fusions; Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen," Hum. Antibod. Hybridomas, Vol. 6, No. 3, 1995, pp. 93-101
	Kishimoto, Tadamitsu et al. (eds.) Leucocyte Typing VI: Proceedings of the Sixth International Workshop and Conference held in Kobe, Japan, 10-14 November 1996, pp. 1218-1219
	Kostelny, Sheri A. et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers," The Journal of Immunology, Vol. 148, No. 5, March 1, 1992, pp. 1547-1553
	Marks, James D. et al., "By-Passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage", J Mol. Biol., Vol. 222, 1991, pp.581-597
	Moore, Kevin L. et al., "Identification of a Specific Glycoprotein Ligand for P-selectin (CD62) on Myeloid Cells," The Journal of Cell Biology, Vol. 118, No. 2, July 1992, pp. 445-456
	Olekswicz, Leslie et al., "Characterization of Tumor-Induced Platelet Aggregation: The Role of Immunorelated GPIb and GPIIb/IIIa Expression by MCF-7 Breast Cancer Cells," Thrombosis Research, Vol. 79, No. 3, 1995, pp. 261-274
	Power, Barbara E. et al., "Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging," Journal of Immunological Methods, Vol. 242, 2000, pp. 193-204
	Ramachandran, Vishwanath et al., "Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow," Proc. Natl. Acad. Sci. USA, Vol. 98, No. 18, August 28, 2001, pp. 10166-10171
	Rodgers, Stephen D. et al., "Tyrosine Sulfation Enhances but is not Required for PSGL-1 Rolling Adhesion on P-Selectin," Biophysical Journal, Vol. 81, October 2001, pp. 2001-2009
	Schmidt, Emmett V. et al., "The Cytomegalovirus Enhancer: a Pan-Active Control Element in Transgenic Mice," Mol. Cell. Biol., Vol. 10, August 1990, pp. 4406-4411
	Snapp, Karen R. et al., "A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P-and L-Selectin," Blood, Vol. 91, No. 1, January 1, 1998, pp. 154-164
	Tomlinson, Stephen, "Complement defense mechanism," Current Opinion in Immunology, Vol. 5, 1993, pp. 83-89
	Varki, A. et al., "P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications," Braz. J. Med. Biol. Res., Vol. 34, No. 6, 2001, pp. 711-717
	Ward, Christopher M. et al., "Mocarhagin, a Novel Cobra Venom Metalloproteinase, Cleaves the Platelet von Willebrand Factor Receptor Glycoprotein Iba. Identification of the Sulfated Tyrosine/Anionic Sequence Tyr-276-Glu-282 of Glycoprotein Iba as a Binding Site for von Willebrand Factor and α -Thrombin," Biochemistry, Vol. 35, No. 15, 1996, pp. 4929-4938
	Wu, AM et al., "Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging," Tumor Targeting, Vol. 4, 1999, pp. 47-58

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	